NCT02591095 - A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

March 31, 2019

Conditions

Platinum-resistant or Refractory Ovarian Cancer

Interventions

DRUG

ABT-263

Trial Locations (16)

CHU Besançon - Hôpital Jean Minjoz, Besançon

Institut Bergonié, Bordeaux

Centre Francois Baclesse, Caen

Centre Oscar Lambret, Lille

Centre Léon Bérard, Lyon

CHU, Lyon

ICM Val d'Aurelle, Montpellier

ICL Institut de Cancérologie de Lorraine, Nancy

Centre Catherine de Sienne, Nantes

ICO Centre René Gauducheau, Nantes

ICO Paul Papin, Nantes

Centre Antoine LACASSAGNE, Nice

Hôpital Européen Georges Pompidou, Paris

Hôpital Tenon, Paris

Institut Claudius Regaud, Toulouse

Gustave Roussy, Villejuif

All Listed Sponsors

collaborator

ARCAGY/ GINECO GROUP

OTHER

collaborator

French Cancer Research Hospital Program

UNKNOWN

lead

Centre Francois Baclesse

OTHER